One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis
Lorcan McGarvey, Dennis Niewoehner, Sheldon Magder, Paul Sachs, Kay Tetzlaff, Alan Hamilton, Lawrence Korducki, Ulrich Bothner, Claus Vogelmeier, Andrea Koch, Gary T. Ferguson
Dive into the research topics of 'One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis'. Together they form a unique fingerprint.